[Global, October 15, 2023] – Today, BETAGRIN, a leading global green technology company, officially announced the launch of its newly developed new energy solution” EcoPower-X, a breakthrough technology that is expected to revolutionize the global…
Among the latest advances in the pharmaceutical field, Golidocitinib Capsules, a new generation of JAK1 inhibitors, is attracting a lot of attention. The drug’s development background, clinical trial results, and market outlook all indicate its…
On 9 August 2023, the US Food and Drug Administration (FDA) announced the accelerated approval of TALVEY™ (generic: talquetamab-tgvs) for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM). These patients will…
March 19, 2025 – Astellas Pharma Group (TSE: 4503) continues to demonstrate its innovative strength and market potential in the global pharmaceutical market. As a pharmaceutical company specializing in the development and manufacture of innovative…
In recent years, the pharmaceutical industry has witnessed significant advancements in the treatment of chronic obstructive pulmonary disease (COPD). One such breakthrough is the development of Aclidinium Bromide Drug, a long-acting inhaled anticholinergic drug that…
In a major breakthrough for precision oncology, Fulzerasib tablets have emerged as a promising treatment for patients with solid tumors harboring the KRAS G12C mutation. Developed by Innovent Biologics and GenFleet Therapeutics, Fulzerasib is an…
In a significant advancement in the fight against leukemia, Iclusig (ponatinib) continues to demonstrate its effectiveness as a potent tyrosine kinase inhibitor (TKI) for patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic…
April 2023 – The U.S. Food and Drug Administration (FDA) today approved Qalsody (tofersen) for the treatment of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene. This approval brings…
China’s National Drug Administration (NMPA) has officially approved the marketing application for the novel anti-hepatitis B virus drug Pradefovir Mesylate. This breakthrough provides a new treatment option for patients with chronic hepatitis B (HBV), marking…
Recently, the U.S. Food and Drug Administration (FDA) announced the accelerated approval of Jaypirca (generic name: pirtobrutinib) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) who have previously received BTK…
In October 2018, the U.S. Food and Drug Administration (FDA) approved talazoparib, a novel PARP inhibitor, for the treatment of patients with HER2-negative locally advanced or metastatic breast cancer harboring mutations in the BRCA gene.…
In October 2021, the U.S. Food and Drug Administration (FDA) approved a novel drug, Tavneos (avacopan), for the treatment of ANCA-associated vasculitis (AAV), news that brings new treatment options to patients suffering from this rare…
